Intellia Therapeutics (NTLA) Share-based Compensation (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Share-based Compensation for 12 consecutive years, with $10.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 51.92% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 89.55% YoY), while the FY2025 annual figure was $80.2 million, down 28.9% from the prior year.
• Share-based Compensation declined to $10.5 million in Q1 2026 per NTLA's latest filing, from $16.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $40.9 million in Q2 2024 and bottomed at -$1.8 million in Q4 2024.
• Historically, Share-based Compensation has averaged $23.1 million across 5 years, with a median of $23.1 million in 2022.
• Annual changes were most pronounced in 2023 — Share-based Compensation jumped 12460.22% — and 2024, when it plunged 105.24%.
• Intellia Therapeutics' Share-based Compensation stood at $279000.0 in 2022, then surged by 12460.22% to $35.0 million in 2023, then slumped by 105.24% to -$1.8 million in 2024, then soared by 1012.21% to $16.7 million in 2025, then plunged by 37.27% to $10.5 million in 2026.
• Business Quant data shows NTLA's Share-based Compensation at $10.5 million in Q1 2026, $16.7 million in Q4 2025, and $7.9 million in Q3 2025.